Paid Clinical Trials Nashville
Discover 1,215 paid clinical trials in Nashville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
Sponsor:
Ribon Therapeutics, Inc.
Location:
Code:
NCT04053673
Conditions
Solid Tumor, Adult
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
RBN-2397
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
Sponsor:
Edwards Lifesciences
Location:
Code:
NCT05172973
Conditions
Aortic Valve Insufficiency
Aortic Valve Stenosis
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
SAPIEN X4 THV
A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06)
Sponsor:
ALX Oncology Inc.
Location:
Code:
NCT05002127
Conditions
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Evorpacept (ALX148)
Trastuzumab
Ramucirumab
Paclitaxel
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Sponsor:
Gilead Sciences
Location:
Code:
NCT03547973
Conditions
Metastatic Urothelial Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sacituzumab Govitecan-hziy
Pembrolizumab
Cisplatin
Avelumab
Zimberelimab
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Sponsor:
American Thrombosis and Hemostasis Network
Location:
Code:
NCT04647227
Conditions
Hemophilia A With Inhibitor
Hemophilia B With Inhibitor
Eligibility Criteria
Sex: All
Age: 12 - 70+
Healthy Volunteers: Not accepted
Interventions
coagulation factor VIIa [recombinant]-jncw
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
Sponsor:
Priovant Therapeutics, Inc.
Location:
Code:
NCT06431373
Conditions
Uveitis, Posterior
Uveitis, Intermediate
Uveitis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Brepocitinib PO QD
Placebo PO QD
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Sponsor:
Dennis M. McNamara, MD, MS
Location:
Code:
NCT05180773
Conditions
Peripartum Cardiomyopathy, Postpartum
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bromocriptine
Placebo
Guideline Directed Medical Therapy for Heart Failure (GDMT)
Rivaroxaban
Second Placebo
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Sponsor:
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Location:
Code:
NCT04471727
Conditions
Small-Cell Lung Cancer
Neuroendocrine Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
MK-6070
Atezolizumab
Ifinatamab Deruxtecan (I-DXd)
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
Sponsor:
Fujifilm Pharmaceuticals U.S.A., Inc.
Location:
Code:
NCT05318573
Conditions
Advanced Urothelial Carcinoma
Advanced Non Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
FF-10832
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
Sponsor:
Ferrer Internacional S.A.
Location:
Code:
NCT06355531
Conditions
Progressive Supranuclear Palsy
Eligibility Criteria
Sex: All
Age: 50 - 70+
Healthy Volunteers: Not accepted
Interventions
FNP-223
Placebo